Publications

8 résultats Voir en premier : les plus pertinents | les plus récents
    • Drogues, Statistiques
    • 2012
    • Article
    • Anglais

    BACKGROUND:
    To determine the seroprevalence of hepatitis B (HBV), hepatitis C (HCV) and HIV infections in problem drug users (PDU) in Luxembourg. To measure the validity of self-reported test results provided by study participants as well as obtained through the national drug-monitoring system (RELIS).
    METHODS:
    In a cross-sectional multisite study, data were collected by voluntary, anonymous and assisted questionnaires and serological detection of antibodies and antigens. Out of 1169 contacts, 397 participants were recruited within in and out-of-treatment settings (84.2% injecting drug users; IDU).
    RESULTS:
    The prevalence of antibodies to HIV was 8/272 (2.9%; 95% CI 0.9% to 4.9%), to HCV 245/343 (71.4%; 66.6% to 76.2%), and 67/310 (21.6%; 17.1% to 26.2%) to total HBV antibodies and surface antigen (for IDU 5/202, 218/268 and 59/239, respectively). Specificity of study self-reports was very high for HBV and perfect for HCV and HIV. Sensitivity was 0.224, 0.798 and 0.800, respectively. Kappa scores provided degrees of agreement between serological tests and study self-reports of 0.89 for HIV, 0.65 for HCV and 0.25 for HBV. In contrast to simultaneous cross-sectional self-reports, secondary self-reported data (RELIS) showed high agreement for HIV and HBV infections and provided a good proxy for estimation of HCV seroprevalence.
    CONCLUSION:
    HIV testing routines in PDU should be completed at least by HBV and HCV detection given the poor validity of cross-sectional self-reports on hepatitis infections. HIV and hepatitis prevalence estimations in PDU gain by relying on multisite/setting data collection. Research should further investigate the validity of HIV and hepatitis self-reports from routine drug-monitoring systems versus cross-sectional surveys.

    Souce: Pubmed

    • Date de parution:
    • Editeur: BMJ
    • Vaccinations, Maladies
    • 2012
    • Communiqué
    • Français, Allemand, Anglais

    Cette fiche d'information, destinée au grand public, fournit des informations sur les symptômes et les complications associées à la grippe, ainsi que recommandations de l'OMS pour la vaccination antigrippale.

    • Date de parution:
    • Editeur: Organisation Mondiale de la Santé (OMS) [World Health Organization (WHO)]
    • Vaccinations, Maladies
    • 2012
    • Communiqué
    • Allemand, Anglais, Français

    Les professionnels de santé peuvent donner cette fiche d'information aux parents pour les aider à informer sur les risques associés aux maladies à prévention vaccinales.

    • Date de parution:
    • Editeur: Organisation Mondiale de la Santé (OMS) [World Health Organization (WHO)]
    • Accidents et blessures
    • 2012
    • Brochure
    • Allemand, Anglais, Français, Portugais

    Recueil d’Informations sur les Traumatismes et Accidents au Luxembourg.

    le Ministère de la Sante en collaboration avec le Centre de Recherche Public de la Santé s’est engagé pour une politique de prévention des accidents dans le cadre du programme européen IDB (Injury Data Base) auquel le Luxembourg adhère. Au niveau national, ce programme porte le nom de RETRACE (REcueil d’informations sur les TRaumatismes et ACcidents au Luxembourg).

    Les accidents sont une des majeures causes de décès, d’hospitalisation et de handicap dans notre pays. Près de 40 000 personnes par année sont victimes d’un accident ou traumatisme au Luxembourg : accidents de la route, du travail, sportif, à domicile ou lors de loisirs.

    Aujourd’hui, nous savons qu’un grand nombre de ces accidents pourrait être évité, si leurs causes et circonstances étaient mieux connues. Pour cela, les informations sur votre accident contribueront à mettre en place des mesures de prévention efficaces et adaptées.

    • Date de parution:
    • Editeur: Ministère de la Santé - Direction de la santé Luxembourg Institute of Health
    • Statistiques, Drogues
    • 2012
    • Article
    • Anglais

    BACKGROUND:
    To estimate the prevalence of problem drug use (PDU) and injecting drug use (IDU) in Luxembourg and analyze trends between 1997 and 2009. To assess the feasibility of prevalence estimations based on drug use surveillance systems.
    METHODS:
    Serial multi-method PDU/IDU prevalence estimations based upon capture-recapture, Poisson regression, multiplier and back-calculation methods. Comparative analysis of methods and assessment of their robustness to variations of external factors.
    RESULTS:
    National PDU and IDU prevalence rates were estimated at 6.16/1,000 (95% CI 4.62/1,000 to 7.81/1,000) and 5.68/1,000 (95% CI 4.53/1,000 to 6.85/1,000) inhabitants aged 15-64 years, respectively. Absolute prevalence and prevalence rates of PDU increased between 1997 and 2000 and declined from 2003 onwards, whereas IDU absolute prevalence and prevalence rates witnessed an increasing trend between 1997 and 2007.
    CONCLUSIONS:
    Drug use surveillance systems can be valuable instruments for the estimation and trend analysis of drug misuse prevalence given multiple methods are applied that rely on serial and representative data from different sources and different settings, control multiple counts and build upon standardized and sustained data collection routines. The described institutional contact indicator revealed to be a useful tool in the context of PDU/IDU prevalence estimations and thus contributes to enhancing evidence-based drug policy planning.

    Souce: Pubmed

    • Date de parution:
    • Editeur: Karger
    • Maladies, Santé sexuelle
    • 2012
    • Communiqué
    • Anglais

    Faits sur l' endométriose].
    Endometriosis is a disease in which tissue similar to the lining inside the uterus (called “the endometrium”), is found outside the uterus, where it induces a chronic inflammatory reaction that may result in scar tissue. It is primarily found on the pelvic peritoneum, ovaries, in the recto-vaginal septum, on the bladder, and bowel. In very rare cases it has been found on the diaphragm and in the lungs.
    Endometriosis affects an estimated 1 in 10 women during their reproductive years (ie. usually between the ages of 15 to 49), which is approximately 176 million women in the world.
    The symptoms of endometriosis include painful periods, painful ovulation, pain during or after sexual intercourse, abnormal bleeding, chronic pelvic pain, fatigue, and infertility, and can impact on general physical, mental, and social well being.
    A general lack of awareness combined with a “normalisation” of symptoms results in a significant delay from when a woman first experiences symptoms until she eventually is diagnosed and treated.

    • Date de parution:
    • Editeur: World Endometriosis Society World Endometriosis Research Foundation
  • Dernière modification le 12-10-2015